These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1507 related items for PubMed ID: 8899193

  • 1. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
    Huss R, Deeg HJ, Gooley T, Bryant E, Leisenring W, Clift R, Buckner CD, Martin P, Storb R, Appelbaum FR.
    Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease.
    Hill RS, Petersen FB, Storb R, Appelbaum FR, Doney K, Dahlberg S, Ramberg R, Thomas ED.
    Blood; 1986 Mar; 67(3):811-6. PubMed ID: 3511988
    [Abstract] [Full Text] [Related]

  • 4. Marrow transplant experience for children with severe aplastic anemia.
    Sanders JE, Storb R, Anasetti C, Deeg HJ, Doney K, Sullivan KM, Witherspoon RP, Hansen J.
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):43-9. PubMed ID: 8311172
    [Abstract] [Full Text] [Related]

  • 5. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
    Lawler M, McCann SR, Marsh JC, Ljungman P, Hows J, Vandenberghe E, O'Riordan J, Locasciulli A, Socié G, Kelly A, Schrezenmeier H, Marin P, Tichelli A, Passweg JR, Dickenson A, Ryan J, Bacigalupo A, Severe Aplastic Anaemia Working Party of the European Blood and Marrow Transplant Group.
    Br J Haematol; 2009 Mar; 144(6):933-45. PubMed ID: 19183198
    [Abstract] [Full Text] [Related]

  • 6. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 7. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience.
    Hernández-Boluda JC, Marín P, Carreras E, Aguilar JL, Grañena A, Rozman C, Montserrat E.
    Haematologica; 1999 Jan; 84(1):26-31. PubMed ID: 10091390
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
    Hamblin M, Marsh JC, Lawler M, McCann SR, Wickham N, Dunlop L, Ball S, Davies EG, Hale G, Waldmann H, Gordon-Smith EC.
    Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
    Chen HR, Ji SQ, Wang HX, Yan HM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG, de Weger RA.
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.
    Phillips GL, Barnett MJ, Brain MC, Chan KW, Huebsch LB, Klingemann HG, Meharchand J, Reece DE, Rybka WB, Shepherd JD.
    Bone Marrow Transplant; 1991 Dec; 8(6):477-87. PubMed ID: 1790428
    [Abstract] [Full Text] [Related]

  • 17. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M.
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [Abstract] [Full Text] [Related]

  • 18. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B, Bogunia-Kubik K, Dlubek D, Jaskula E, Sok A, Drabczak-Skrzypek D, Sedzimirska M, Lange A.
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T, Van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Ferrara GB, Delfino L, Pozzi S, Morabito A, Zikos P, Vitale V, Corvo R, Frassoni F, Bacigalupo A.
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.